Arrival of carbapenem-hydrolyzing-oxacillinases in Acinetobacter baumannii in Bosnia and Herzegovina by Petrović, Tanja et al.
  
    
 
Središnja medicinska knjižnica 
 
 
 
 
Petrović T., Uzunović S., Barišić I., Luxner J., Grisold A., Zarfel G., 
Ibrahimagić A., Jakovac S., Slaćanac D., Bedenić B. (2018) Arrival of 
carbapenem-hydrolyzing-oxacillinases in Acinetobacter baumannii in 
Bosnia and Herzegovina.  Infection, genetics and evolution: journal of 
molecular epidemiology and evolutionary genetics in infectious 
diseases, 58. pp. 192-198. ISSN 1567-1348 
 
 
http://www.elsevier.com/locate/issn/15671348 
 
http://www.sciencedirect.com/science/journal/15671348 
 
https://doi.org/10.1016/j.meegid.2017.12.021 
 
http://medlib.mef.hr/3352 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
   
 
 
 
 
 
ARRIVAL OF CARBAPENEM- HYDROLYZING- OXACILLINASES IN 
ACINETOBACTER BAUMANNII IN BOSNIA AND HERZEGOVINA 
 
Tanja Petrovića, Selma Uzunovićb, Ivan Barišićc, Josefa Luxnerd , Andrea Grisoldd, Gernot 
Zarfeld, ,  Amir Ibrahimagićb  ,  Sanja Jakovaca , Domagoj Slaćanace and Branka Bedeniće,f  
 
aUniversity Hospital Mostar 
bDepartment for Laboratory Diagnostics, Cantonal Public Health Institute Zenica, Bosnia and 
Herzegovina 
c IT, Austrian Institute for Technology, Molecular Diagnostic, Vienna, Austria 
dInstitute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, 
Neue Stiftingtalstrasse Graz, Austria 
eDepartment of Microbiology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia 
fDepartment of Clinical and Molecular Microbiology, University Hospital Center Zagreb,  
Zagreb, Croatia 
Corresponding author. Branka Bedenić; Department of Microbiology, School of Medicine, 
University of Zagreb, Salata 3b, 10000 Zagreb, Croatia, Department of Clinical and Molecular 
Microbiology, University Hospital Center Zagreb, Kispatic Street 12, 10000 Zagreb, Croatia; tel 
00385 1 23 67 304; 00385 1 23 67 393; branka.bedenic@kbc-zagreb.hr 
 
E-mail addresses: branka.bedenic@kbc-zagreb.hr (B. Bedenić), josefa.luxner@medunigraz.at (J. 
Luxner), Ivan Barišić Ivan.Barisic@ait.ac.at>, gernot.zarfel@medunigraz.at (G. Zarfel), , 
andrea.grisold@medunigraz.at (A. Grisold): ibrahimagic.amir@gmail.com (A. Ibrahimagić); 
selma_kamb@yahoo.com (Selma Uzunović); domagoj.slacanac@gmail.com (D. Slaćanac); 
sanjamaljkovic@yahoo.com (S. Jakovac),  tnjptrvc@yahoo.co.uk (T. Petrović) 
 
 
1 
 
 
 
ABSTRACT 
Multidrug-resistant Acinetobacter baumannii (MDR-AB)  is an important threat for critically 
ill patients. It can infect the respiratory tract, blood, soft tissues, urinary tract and central 
nervous system. Recently, carbapenem-resistance was observed in A. baumannii clinical 
isolates from Bosnia and Herzegovina.  This prompted us to analyze these isolates with 
regards to genotypic diversity, antibiotic susceptibility and occurrence of acquired 
carbapenem resistance genes. Twelve carbapenem-resistant isolates were collected at a 
University hospital during two different periods of 2011 and 2015-2016:   four isolates in 
2011 and eight isolates 2015-2016 and compared to determine the dynamic changes in 
carbapenemase resistance mechanisms and population structure. All twelve isolates were 
positive for intrinsic blaOXA-51-like, nine for  blaOXA-40-like   and one for the blaOXA-23-like  gene. 
ISAba1 was found upstream of blaOXA-51 in all and upstream of blaOXA-23-like  gene in one 
isolate. Sequencing of the selected PCR products revealed the presence of OXA-72 β-
lactamase (strain 1) and OXA-23 β-lactamase (strain 41).  WGS of the selected isolate (AB 5) 
revealed the presence of blaOXA-72, chromosomal genes blaOXA-69 and blaADC. Moreover, the 
aac (3)-1a and aadA1 genes encoding aminoglycoside resistance, and sul1encoding 
sulphonamide resistance were identified. PFGE and rep-PCR revealed two clones containing 
highly similar isolates positive for OXA-40-like; one from 2011 and the other from 2015-
2016.  
Implementation of hospital hygiene measures, screening of the patients on admission for 
carriage of MDR-AB, and the early and accurate detection, with restriction of antibiotic use 
should be recommended to control the spread of these important hospital pathogenes.  To our 
knowledge, this is the first report of A. baumannii isolates producing carbapenem-hydrolyzing 
oxacillinases (CHDL) from Bosnia and Herzegovina.  
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1.Introduction 
Multidrug- resistant Acinetobacter baumannii (MDR-AB) is an important threat for critically 
ill patients (Coelho et al., 2004). It can infect the respiratory tract, blood, soft tissues, urinary 
tract and central nervous system.  This organism is frequently resistant to multiple 
antimicrobial agents and there are recent reports on isolates that are pandrug-resistant bacteria 
(Livermore and Woodford, 2006; Durante-Mangoni et al, 2014).  Hospital outbreaks are 
usuall associated with clusters of highly similar strains which are designated as International 
clonal lineages I, II and III or worldwide clonal lineages (Nemec et al., 2008). Carbapenem 
resistance is usually associated with ICL II. Resistance to carabapenems can be due to 
impaired permeability or alternation in penicillin-binding proteins (Poirel and Nordmann, 
2006). However, β-lactamase-mediated resistance is the most common mechanism of 
carbapenem resistance in this species. Carbapenemases found in Acinetobacter spp. belong to 
molecular class A (KPC) (Robledo et al., 2010), class B (metallo-β-lactamases of IMP, VIM,  
SIM or NDM family) (Lee et al., 2005; Cornaglia et al., 1999; Hrabak et al., 2012; Perilli et 
al., 2011) or class D (OXA enzymes) recently  known as CHDL (carbapenem-hydrolyzing 
class D oxacillinases) (Brown and Amyes, 2006). The OXA enzymes of Acinetobacter are 
classified into five phylogenetic groups comprising the in A. baumannii intrinsic OXA-51-like 
and the acquired enzymes: OXA-23-like, OXA-24/40-like,  OXA-58- like, OXA-143-like and 
OXA-235-like (Brown and Amyes, 2006; Higgins et al., 2009). Enzymes belonging to OXA-
51 group are naturally occuring β-lactamases of A. baumannii and are normally expressed at 
low levels but can be overexpressed as a consequence of the ISAba1 location upstream of the 
genes (Turton et al., 2006). Recently carbapenem-resistance was observed in A. baumannii 
from Bosnia and Herzegovina.  This geographic region is characterised by a great cultural 
diversity and population mixing. Thus, the molecular characterization and strain typing of 
such epidemic isolates is important for the identification of the sources and the mode of 
spread, in order to develop the targetted infection control strategies.  This prompted us to 
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analyze these isolates with regards to genetic diversity, antibiotic susceptibility and 
occurrence of acquired carbapenem resistance genes. The previous studies from 2009 found 
that reduced susceptibility in A. baumannii from Bosnia was solely atributed to 
overexpression of intrinsic OXA-51 β-lactamase with ISAba1 upstream of the gene 
(Ibrahimagić et al, 2017). The new isolates were collected during two periods: in 2011 and 
2015 and compared to determine the dynamic changes in carbapenemase resistance 
mechanisms and the population structure.    
 
2. Material and methods 
2.1Bacterial isolates 
Twelve MDR-AB were collected at the University Hospital Mostar in Bosnia and 
Herzegovina. The University Hospital Mostar is a tertiary hospital with 900 beds, covering a 
population of 400 000 inhabitants.  Four  non-duplicate (one per patient), consecutive isolates 
were collected from  July 2011 to November 2011. The remaining eight consecutive non-
duplicate isolates were collected from November 2015 till January 2016.  Two periods were 
selected in order to study the dynamic changes in the epidemiology of carbapenem-resistance 
in a major opportunistic pathogen such as A. baumannii. The total number of A. baumannii 
isolates in the first study period (July to November 2011) was 131 with four showing 
carbapenem-resistance (3%). In the second study period (November 2015 to January 2016) 
the rate of carbapenem resistant  A. baumannii was 9 % (7/73). The isolates originated from 
nephrology, surgical ICU and urology hospital ward with two isolates being obtained from 
outpatients previously hospitalized in the same hospital. Eight isolates were obtained from 
patients with signs and symptoms of infection and four from colonized patients according to 
standard infection definitions (Horan et al., 2008).  
2.2Susceptibility tests and β-lactamase detection 
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The antimicrobial susceptibility to ceftazidime, cefotaxime, ceftriaxone, cefepime, imipenem, 
meropenem, gentamicin, ciprofloxacin, tigecycline and colistin was determined by disk-
diffusion and broth microdilution method in 96 well microtiter plates and interpreted 
according to CLSI breakpoints (Clinical Laboratory Standards Institute, 2014). Minimum 
inhibitory concentrations (MICs) of imipenem and meropenem were determined also by agar 
dilution with addition of cloxacillin (200 mg/L) and  sodium chloride in order to determine 
the effect of chromosomal AmpC β-lactamases on the susceptibility to carbapenems and to 
detect enzymes of OXA-58 group which  are susceptible to inhibition with sodium chloride, 
respectively (Pournaras et al., 2006). The isolates were classified as multidrug-resistant, 
extensively drug resistant or pan drug resistant bacteria (Magiorakis et al., 2012). 
Extended-spectrum β-lactamases (ESBLs) were detected by combined disk test with 
cephalosporins and clavulanic acid according to CLSI with addition of cloxacillin in the 
medium (200 mg/L) (Clinical Laboratory Standards Institute, 2014) to inhibit the 
chromosomal AmpC β-lactamase which can antagonize the synergistic effect with 
clavulanate. Augmentation of the inhibition zones around ceftazidime, and cefepime disks of 
at least five mm in the presence of clavulanic acid was considered indicative of ESBL 
production. 
A modified Hodge test (MHT) was used to screen for the production of carbapenemases (Lee 
et al., 2003). Additionally the isolates were tested by combined disk tests with imipenem and 
meropenem alone and combined with 3-aminophenylboronic acid test (PBA), 0.1 M EDTA or 
both to screen for KPC, MBLs, or simultaneous production of KPC and MBL, respectively 
(Pasteran et al 2009).  
2.3. Molecular detection of resistance genes 
The genes conferring resistance to β-lactams including broad spectrum and extended-
spectrum β-lactamases (blaSHV, blaTEM, blaCTX- blaGES and blaPER-1) (Nuesch-Inderbinen et al., 
1996; Arlet et al., 1995; Woodford et al., 2004; Pagani et al., 2004; Bonnin et al, 2011.,), class 
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A carbapenemases (blaKPC, ) (Robledo, et al., 2010) , class B (blaVIM, blaIMP and blaNDM) 
(Poirel et al., 2011), and CHDL (blaOXA-51-like, blaOXA-23-like, blaOXA-40-like, blaOXA-58-like and 
blaOXA-143-like) (Woodford et al., 2006) were determined by PCR as previously described.  
Reference strains producing SHV-1, SHV-2, TEM-1, CTX-M-15, IMP-1, VIM-1, KPC-2, 
OXA-23, OXA-40, OXA-58 and OXA-143 were used as positive control strains. The PCR 
product were purified by using the QIA DNA minikit (Inel, Zagreb, Croatia) and  the selected 
amplicons (strain 1- blaOXA-40 and strain 41-blaOXA-23) were sequenced by the Eurofins 
sequencing services (Eurofins Genomics GmbH, Ebersberg, Germany). The genetic context 
of blaOXA-51 and blaOXA-23 genes was further investigated by PCR mapping with primers for 
ISAba1 combined with forward and reverse primers for blaOXA-51 and blaOXA-23 (Turton et al., 
2006). 
Isolate 5 was randomly selected for further whole genome sequencing (WGS). The bacterial 
genomes were sequenced using the IonTorrent PGM platform (Life Technologies, Carlsbad, 
USA) according to the manufacturer's instructions. The Ion Xpress Plus Fragment Library Kit 
was used to enzymatically shear 100 ng of the genomic DNA. The target fragment size was 
400 bp. Subsequently, the fragmented DNA was processed using the Ion DNA Barcoding kit 
(Life Technologies) and its size selected using the E-Gel SizeSelect 2% Agarose kit (Life 
Technologies). The size distribution of the DNA fragments was analysed using the High 
Sensitivity Kit (Agilent, Santa Clara, USA). Further sample processing was performed using 
the Ion OneTouch Kit (Life Technologies). Finally, the amplified DNA was sequenced using 
the 318 chip (Life Technologies). The single reads obtained were de novo assembled using 
MIRA 3.9.9, which is part of the Assembler plugin on the Ion Torrent server. Subsequently, 
the contigs were aligned to a reference genome of the corresponding species using Mauve and 
submitted to the RAST analysis platform (Gan et al., 2015). RAST is an automated annotation 
platform for bacterial genomes. The annotated genes were screened in RAST for antibiotic 
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resistance genes and their genetical context. Additionally, the contigs were analyzed using the 
ResFinder web-service (Zankari et al., 2012).  
 2.4. Characterization of plasmids 
The transferability of meropenem resistance was determined by conjugation (broth mating 
method) employing  E. coli J65 resistant to sodium azide (Elwell and Falkow, 1986). 
Plasmids were extracted with Qiagen Mini kit according to the manufacturer’s instructions 
and subjected to transformation experiments using A. baumannii ATCC 19606 as recipient 
(Choi et al., 2006).  PCR-based replicon typing (PBRT) was applied to type the resistance 
plasmids carrying carbapenemase genes according to Bertini for A. baumannii (Bertini et al., 
2010).  
2.5. Genotyping 
Sequence groups of A. baumannii (SGs 1-3) corresponding to international clonal lineages 
(ICL I-III) were determined according to the procedure described by Turton et al. (Turton et 
al., 2007). PFGE genotyping of Apa I-digested genomic DNA was performed on eleven out of 
twelve isolates (1, 2, 4, 5, 11, 17, 41, 42, 43, 44 and 45) with a CHEF-DRIII system (Bio-
Rad); the images were processed using Gel-Compar software. The dendrogram was computed 
after band intensity correlation using global alignment with 1.5 % optimization and tolerance 
and UPGMA (unweighted pair-group method using arithmetical averages) clustering. The 
strains were considered to be clonally related if they showed more than 80 % similarity of 
their PFGE patterns (Kaufman, 1998; Tenover et al., 1995).  
Ten (1, 2, 4, 5 and 17, 41, 42, 43, 44, and 45) were subjected to molecular typing by rep-PCR 
as described previously (Overdest et al, 2011). DNA was isolated by Ultra-Clean microbial 
DNA isolation kit (Mo Bio Laboratories, Carlsbad, CA, USA), as recommended by the 
manufacturer. The DNA concentration was measured and set between 25 ng/L and 30 ng/L. 
Subsequently, the DNA was amplified using the Bacterial fingerprinting kit (Bacterial 
barcodes, bioMerieux, Athens, GA, USA), according to the manufacturer’s instructions. All 
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data were entered in the DiversiLab software system. Cut-off value of 97% was used to define 
a clone (Healy et al., 2005).  
Seven  isolates (1, 2, 41, 42, 43, 44  and 45) were also genotyped by MLST according to 
protocols on Pasteur website.  
 
3. Results 
3.1. Bacterial isolates 
The isolates were identified by conventional biochemical tests and  MALDI-TOF, and 
confirmed as A. baumannii by the  presence of the intrinsic blaOXA-51 gene. The patients did 
not have a history of a travel abroad within three months before the sample collection.  
3.2. Susceptibility tests and β-lactamase detection 
All isolates except AB 11,  and AB 45, were uniformly resistant to third generation 
cephalosporins, cefepime, piperacillin/tazobactam, imipenem, meropenem, gentamicin and 
ciprofloxacin and susceptible to colistin. All but one isolate were susceptible to tigecycline as 
shown in Table 1. Apart of the isolates 11, and 45,  all were classified as extensively drug 
resistant according to Magiorakos et al. The addition of NaCl and cloxacillin did not lower the 
MICs of carbapenems indicating the absence of OXA-58 and lack of  hyperproduction of 
chromosomal AmpC β-lactamase. All isolates tested negative in combined disk test with 
clavulanic acid indicating the lack of an ESBL. The production of class B carbapenemase was 
suspected based on positive inhibitor based test with EDTA.  
3.3. Molecular detection of resistance genes 
All isolates were positive for blaOXA-51-like, nine for  blaOXA-40-like  genes and one for  blaOXA-23-
like gene. Reduced susceptibility to carbapenems in two isolates (11 and 45) was associated 
with ISAba1  upstream of blaOXA-51. PCR was negative for ESBLs reported in A. baumannii 
so far. Sequencing of the selected PCR products revealed OXA-72 β-lactamase (strain 1 and 
OXA-23 β-lactamase (strain 41).   MBLs were not found among the isolates. WGS of the 
8 
 
 
 
strain 5 revealed the presence of blaOXA-72, chromosomal genes blaOXA-69 and blaADC in the 
isolate 5. Moreover, the genes aac(3)-Ia and aadA1 encoding aminoglycoside resistance and 
sul1 encoding sulphonamide resistance were identified. Furthermore, virulence genes such as 
htpB encoding heat shock protein, man B for phosphomanomutasel, pilF for type IV pilus 
assembly, IspE for general secretion pathway protein E, clpP for ATP-dependent Clp 
protease, tviB for polysaccharide biosynthesis protein, endopeptidase Cip ATP protein chain, 
lpxC for UDP-3-O-3-hydroxymyristail acetylglucosamin, gspE-general secretion pathway 
protein, fepA for ferrienterobactin outer membrane transportation system, capD for capsular 
polysaccharide synthesis enzyme and many other virulence factors were detected by WGS.  
The sequence is deposited in the Gene bank with the accession number PRJEB23482.  
3.4. Characterization of plasmids 
Repeated attempts failed to transfer imipenem resistance from each of eleven isolates to E. 
coli recipient strain by conjugation or  to A. baumannii ATCC 19606 by transfomation.  
PBRT was negative for any of the plasmid inocompatibility groups reported in A. baumannii 
so far,  except of  the strain 41 with OXA23 which-belonged to Inc group 6 encoding aci6-
replicase gene originally found on plasmid pACICU2.   
3.5. Genotyping 
Rep-PCR and PFGE identified two distinct clusters with OXA-40 positive isolates: one 
containing four isolates from 2011 (1, 2, 4 and 5) and the other comprising three isolates from 
2015 (42, 43 and 44) whereas the isolate 17 from 2015 showed distinct rep-PCR profile 
(Figure 1a, Figure 2). A certain degree of diversification was observed among the isolates 
belonging to the same cluster.  (Figure 2).  Four isolates were singletons by PFGE (11, 17, 41 
and 45).  All isolates belonged to IC I (SG 2).  Since blaOXA-72 has been associated with 
isolates belonging to IC I we compared the rep-PCR profiles obtained in this study with 
OXA-72 positive isolates from an outbreak in a nursing home in Zagreb which also belonged 
to IC I and the isolates from 2011 matched with 97% similarity with those from Zagreb 
9 
 
 
 
(Figure 1b).  Two isolates from 2011 (1 and 2) were found to belong to ST 642 whereas five 
from 2015 (41, 42, 43, 44 and 45) were allocated to ST636.  
 
4. Discussion 
Carbapenem-resistant A. baumannii are a source of deep concerns due to its multidrug 
resistance properties and ability to persist in the environment and cause outbreaks in the 
hospital setting.  Three different carbapenem resistance mechanisms were involved: OXA-72 
β-lactamase belonging to OXA-40- like group, OXA-23 β-lactamase and upregulation of 
OXA-51 β-lactamase by ISAba1.  The study performed in 2009 found that reduced 
susceptibility to carbapenems was associated only with upregulation of blaOXA-51 gene by 
ISAba1 (Ibrahimagić et al., 2017).   In this study a shift to CHDL was observed 
 Sequencing of blaOXA-40 gene revealed the OXA-72 allelic variant associated with high level 
of resistance to carbapenems.  This type of CHDL with similar properties was previously 
reported in two hospital centers in the neighbouring Croatia and also in the nursing home in 
Zagreb (Goić-Barišić et al., 2011; Franolić-Kukina et al., 2011; Bedenić et al., 2015).  The  
OXA-72 β-lactamase with similar properties was previously reported in France (Barnaud et 
al., 2010), South Korea (Lee et al., 2009), Taiwan (Lu et al., 2009), China (Wang et al., 2007), 
Brazil (Werneck et al., 2010) and Serbia (Dortet et al., 2015).  Similarily as in our study, they 
proved the chromosomal location of blaOXA-72 gene.  
OXA-23 was found in only one isolates. This type of CHDL is widespread and reported all 
over the world (Towner et al, 2007, Coelho et al, 2004, Zong et al, 2008).   It was reported 
previously from two hospital centers in Zagreb (Vranić-Ladavac et al., 2014) in the multicenter 
study conducted in 2009-2010 and it was also previously found in a nursing home in Zagreb, 
Croatia (Bedenić et al., 2015) which is a neighbouring country to Bosnia. The isolate carrying 
blaOXA-23 gene was found to be less resistant to carbapenems compared to highly resistant 
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isolates harbouring blaOXA-40-like genes.  The majority of studies proved plasmid location of 
OXA-23 gene, but in our study transformation experiments failed. However, the OXA-23 
positive isolate was found to posses the plasmid belonging to Inc 6 group by PBRT. Unlike 
the isolates from Croatia which were associated with outbreaks (Vranić-Ladavac et al, 2013) 
the isolate from Bosnia was single.  
PFGE and rep-PCR revealed two distinct clones harbouring OXA-40-like positive isolates 
one from 2011 and the other from 2015-2016, both containing highly similar isolates. High 
genetic similarity of the isolates could be due to the fact that the isolates were obtained from 
the same hospital over a short time period, which might indicate cross infection. However, the 
isolates originating from different time periods demonstrated diverse banding patterns 
generated by PFGE and rep-PCR,  thus showing a dynamic changes in the population 
structure and pointing out to the introduction of a new clone.. The isolates from Bosnia 
positive for OXA-72 from 2011  clustered together with those from a nursing home in Zagreb 
collected in 2012,  also positive for OXA-72, indicating the ability of isolates for crossing 
borders. The origin of this clone remains unclear, as it is the reason for its epidemic success. It 
is very likely that the spread occurred via patient transfer, but there is no direct epidemiologic 
proof of this view, and it remains possible that the isolates at different location have arisen by 
independent events. PFGE is still considered to be a gold standard in genotyping of A. 
baumannii. High correspondence between pattern differentiations produced by rep-PCR and 
PFGE was observed with PFGE being more discriminative. Two isolates 41 and 45 were 
classified as pair by rep-PCR and as  singletons by PFGE which could be explained by better 
discriminatory power of PFGE.  A link between the carbapenemase gene, PFGE and rep-PCR 
typing results was observed, suggesting that the both methods could effectively be applied for 
epidemiologic typing of A. baumannii.   The main drawback of PFGE is the lack of portability 
of typing results. Interestingly, all imipenem-susceptible A. baumannii isolates belonged to IC 
I. Carbapenem-resistance was strongly associated with IC 1, in contrast to other studies in 
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which it was linked to IC 2 (Healy et al., 2005; Nemec et al, 2008).  The ST 642 associated 
with two OXA-40 positive isolates from 2011,  is rare and was previously reported in 
Mongolia (Kao et al., 2014).  All isolates from 2015 belonged to ST 636, confirming the 
introduction of a new clone in 2015. This ST was previously reported in Colombia (Correa et 
al, 2017). Interestingly, all isolates from 2015 including those with OXA-40-like and OXA-
23-like genes belonged to ST636 pointing out to the absence of link between population 
structure and resistance gene content.  Different genotyping methods were applied because 
PFGE is more suitable for outbreak analysis whereas MLST and rep-PCR, as portable 
methods, enable international and interlaboratory comparison of the isolates.  The 
dissemination of MDR-AB in various clinical wards within the hospital was observed 
including surgery, neurology, medical ICU and urology. The fact that also outpatients were 
also colonized points out to the dissemination of MDR-AB into the community setting.  
All imipenem-resistant isolates were phenotypically suspected for MBLs, but PCR for 
common MBLs was negative. False positive results in inhibitor based tests can occur because 
in the presence of EDTA oxacillinase is converted to a less active state leading to the 
augmentation of the inhibition zone around the carbapenem disk (Vilalon et al., 2011).  Many 
virulence factors found in WGS contribute to the severity of diseases associated with MDR-
AB.The drawback of the study is relatively small number of isolate and the fact that outbreak 
isolates were compared with non-outbreak. Unfortunately, the isolates were not collected in 
the period between 2011 and 2015 to analyze the evolution of carbapenem-resistance and 
MDR-AB genotypes in the meantime.  
Implementation of hospital hygiene measures, and the early and accurate detection, with 
restriction of antibiotic use should be recommended to control the spread of these important 
hospital pathogens.  Moreover, surveillance programs to monitor antibiotic resistance in A. 
baumannii should be implemented. Bosnia and Herzegovina is a epidemiologically interesting 
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region with a great diversity and population mixing and representing a possible reservoir for 
multiresistant pathogens.  
 
FIGURE LEGEND 
Figure 1a. Rep-PCR dendrogram of ten representative isolates.  Specimen, date of colection, 
and hospital unit are shown.  Cut off value of 97% similarity was applied to define a clone.  
Existence of two clusters is visible.  
Figure 1b. Comparison of Rep-PCR profiles of isolates from Mostar with  those from Zagreb.  
Figure 2. PFGE dendrogram of 11 A. baumannii isolates from two periods. Cut off value of 
80% similarity was applied to define a clone. Specimen, hospital unit, and date of isolation  
are shown.  Existence of two clusters is visible.  
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